Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

Not Applicable

Recruiting

• Conditions: Multiple Myeloma

• Registration Number: NCT05945524
• Lead Sponsor: University Hospital, Toulouse

Brief Summary

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-05-16
• Study First Submitted QC: 2023-07-11
• Study First Posted: 2023-07-14
• Study Start: 2023-09-28
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-07
• Last Update Posted: 2025-04-10
• Primary Completion: 2026-03-31
• Study Completion: 2026-05-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• With multiple myeloma
• Who receive Teclistamab
• Consent form signed

Exclusion Criteria

• Patient under legal protection

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Response to teclistamab at 12 weeks	at day 1 Cycle 4 (each cycle is 28 days)	response according to International Myeloma Working Group criteria

Trial Locations

Locations (18)

CHU d'Amiens; 🇫🇷 Amiens, France

CHU de Caen; 🇫🇷 Caen, France

Polyclinique du Parc Drevon; 🇫🇷 Dijon, France

CH Annecy Genevois; 🇫🇷 Epagny Metz- Tessy, France

CHU de Lille; 🇫🇷 Lille, France

Centre Léon Bérard; 🇫🇷 Lyon, France

CHU de Montpellier; 🇫🇷 Montpellier, France

Hôpital Saint-Louis; 🇫🇷 Paris, France

Hôpital Saint-Antoine; 🇫🇷 Paris, France

Hôpital Necker; 🇫🇷 Paris, France

Scroll for more (8 remaining)